Company Profile

Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.

Latest News

How Lisa Su Has Positioned AMD to Be a Big AI Winner and Why the Stock Is a Buy

Motley Fool • 07/27/2026

Share buybacks in Ericsson during the period July 20 - July 24, 2026

PR Newswire • 07/27/2026

OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside

Stocktwits • 07/27/2026

Canon: Q2 Earnings Snapshot

Associated Press • 07/27/2026

Temenos Named One of World’s Top Fintech Companies by CNBC

GlobeNewswire • 07/27/2026